Essilor: 2012 Registration Document Filed

Wed Apr 3, 2013 11:57am EDT

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130403:nBw036107a

CHARENTON-LE-PONT, France--(Business Wire)--
Regulatory News: 

The 2012 Essilor (Paris:EI) Registration Document was filed in French version
with the Autorité des Marchés Financiers (AMF) on April 2, 2013 under the number
D.13-0252. The Registration Document includes: 

a) The Annual Financial Report, with:

* The parent company financial statements; 
* The consolidated financial statements; 
* A management report containing information in compliance with articles
L.225-100, L.225-100-3, L.225-11 (§ 2) and L.225-100-2 of the French Commercial
Code; 
* A statement by the persons responsible for the Registration Document; 
* The report of the Auditors on the parent company and consolidated financial
statements; 
* Information concerning Auditors` fees.

b) The Chairman`s report on corporate governance and internal control. 

c) The description of the share buyback program. 

From now on, the French version is available to the public free of charge, as
provided for in applicable legislation, and may be viewed on Essilor`s corporate
website www.essilor.com. The English version will be available in a few days. 

About Essilor

The world`s leading ophthalmic optics company, Essilor designs, manufactures and
markets a wide range of lenses to improve and protect eyesight. Its corporate
mission is to enable everyone around the world to access lenses that meet his or
her unique vision requirements. To support this mission, the Company allocates
more than €150 million to research and innovation every year, in a commitment to
continuously bring new, more effective products to market. Essilor`s flagship
brands are Varilux®, Crizal®, Definity®, Xperio®, OptifogTM and Foster Grant®.
It also develops and markets equipment, instruments and services for eyecare
professionals.

Essilor reported consolidated revenue of approximately €5 billion in 2012 and
employs around 50,700 people in some 100 countries. It operates 22 plants, more
than 400 prescription laboratories and edging facilities, as well as several
research and development centers around the world.

For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in
the Euro Stoxx 50 and CAC 40 indices.

Codes and symbols: ISIN: FR FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16 

Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.